WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company that develops anticancer therapeutics using its antibody
expertise and Targeted Antibody Payload (TAP) technology, today
announced that the following presentations by Company management at
upcoming investor conferences will be webcast:
-
Stifel Nicolaus 2012 Healthcare Conference
10:55 am ET on
September 5, 2012 in Boston, MA
Presenter: Gregory Perry,
Executive Vice President and CFO
-
Morgan Stanley Global Healthcare Conference
8:00 am ET on
September 12, 2012 in New York, NY
Presenter: Daniel Junius,
President and CEO
-
UBS Global Life Sciences Conference
3:00 pm ET on
September 20, 2012 in New York, NY
Presenter: Daniel Junius,
President and CEO
A webcast of each presentation can be accessed live through the
"Investor Information" section of the Company's website, www.immunogen.com;
a replay of each presentation will be available at the same location for
one week.
The Company is also participating in the Credit Suisse 3rd
Annual Small & Mid Cap Conference on September 21, 2012 in New York, NY.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's TAP
technology uses monoclonal antibodies to deliver one of ImmunoGen's
proprietary cancer-killing agents specifically to tumor cells. There are
now ten TAP compounds in clinical development, of which three are wholly
owned by the Company. ImmunoGen's collaborative partners include Amgen,
Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. A
marketing application for trastuzumab emtansine (T-DM1), the most
advanced compound using ImmunoGen's TAP technology, has been submitted
in the US. Roche is developing this compound under an agreement between
ImmunoGen and Genentech, a member of the Roche Group. More information
about ImmunoGen can be found at www.immunogen.com.
Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
Source: ImmunoGen, Inc.
News Provided by Acquire Media